Cargando…
Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
BACKGROUND. A phase III trial compared lapatinib plus letrozole (L + Let) with letrozole plus placebo (Let) as first-line therapy for hormone receptor (HR)(+) metastatic breast cancer (MBC) patients. The primary endpoint of progression-free survival (PFS) in patients whose tumors were human epiderma...
Autores principales: | Sherrill, Beth, Amonkar, Mayur M., Sherif, Bintu, Maltzman, Julie, O'Rourke, Lisa, Johnston, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228031/ https://www.ncbi.nlm.nih.gov/pubmed/20798196 http://dx.doi.org/10.1634/theoncologist.2010-0012 |
Ejemplares similares
-
Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2010) -
Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
por: Cameron, David, et al.
Publicado: (2010) -
Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review
por: Rosen, Lee S., et al.
Publicado: (2010) -
Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
por: Extra, Jean-Marc, et al.
Publicado: (2010) -
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
por: Ludwig, Heinz, et al.
Publicado: (2010)